How much funding has Alivexis raised?

Alivexis has raised $26.4M in total funding, most recently a Series D round.

Where is Alivexis headquartered?

Alivexis is headquartered in Tokyo, Japan.

What industry is Alivexis in?

Alivexis operates in Artificial Intelligence, Biotech.

Alivexis

Q: Who are Alivexis's investors?

Alivexis's investors include JIC Venture Growth Investments, DBJ Capital Corporation, Fast Track Initiative,.

Home | Alivexis, Inc.

Tokyo, Japan · Founded 2016 · $26.4M raised

Artificial Intelligence

Biotech

Headquarters: Tokyo
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: alivexis.com
Total Funding: $26.4M
Last Round: $6.0M Series DJan 2025
Rounds: 2

About

Alivexis, Inc. (formerly Modulus Discovery) is a technology-driven drug discovery enterprise with operations in both Tokyo, Japan and the United States. The company leverages its proprietary ModBind computational platform — which uses GPU-optimized molecular simulation and AI — to discover novel small-molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases. Alivexis pursues an asset-light, network-based R&D model, partnering with global pharmaceutical companies including Astellas Pharma, and has advanced multiple clinical candidates through its portfolio of discovery programs since its founding in August 2016.

Summary

Alivexis is an Artificial Intelligence company based in Tokyo, Japan, founded in 2016. It has raised $26.4M in total across 2 rounds, most recently a $6.0M Series D round in Jan 2025. Investors include JIC Venture Growth Investments, DBJ Capital Corporation and Fast Track Initiative,.